AbbVie (ABBV) Company Report

Medincell’s total income rose 50% YoY to €14.1 m, with revenues of €11.6 m up 35% versus H1 FY2024.
Operating expenses increased 22% to €20.8 m, resulting in an operating loss of €6.6 m, a 13% improvement year-over-year.
Cash and equivalents plus low-risk financial investments stood at €53.5 m at September 30, 2025.
UZEDY® royalties climbed 50% to €4.2 m, and Teva submitted an NDA for Olanzapine LAI to the FDA on December 9, 2025.
Collaboration with AbbVie advanced preclinical and CMC activities, with a regulatory package for first human trials expected in 2026.

Dec 9, 2025, 5:02 PM

Press Release

Roche presents Lunsumio data showing potential across earlier treatment lines in indolent and aggressive lymphomas

ABBV

Preliminary data from the US extension of the phase III CELESTIMO study showed an 87.0% complete response rate and 27.8% CRS incidence (mostly Grade 1–2) in 54 patients with second-line+ follicular lymphoma
In the phase Ib/II GO40516 study for relapsed/refractory large B-cell lymphoma, subcutaneous Lunsumio plus polatuzumab vedotin delivered a 77.5% ORR vs 50.0% and median PFS of 25.4 vs 6.4 months compared to rituximab/Polivy
Five-year follow-up of IV Lunsumio in third-line+ FL reported a 78.5% overall survival rate and 54-month duration of CR rate of 52.0%; three-year SC data showed 74.5% ORR, 62.8% CR and a 30-month DOCR of 53.0%
Lunsumio monotherapy is approved in over 60 countries, with the SC formulation recently approved by the European Commission and a US FDA decision expected soon

Dec 8, 2025, 9:30 PM

Press Release

AbbVie reports Phase 1b/2 EPCORE-CLL-1 epcoritamab data in Richter transformation

ABBV

Monotherapy arm (Arm 2A) in RT patients (n=42) showed an ORR of 57% (52% CR) first-line and 38% (29% CR) later-line; median OS was 27.5 months and 9.8 months, with median PFS of 8.5 and 2.9 months, respectively.
Epcoritamab + lenalidomide (Arm 2B) in previously treated RT (n=11) achieved an ORR of 82% and CR rate of 73%; median PFS was 5.7 months, and 9-month OS was not reached.
Epcoritamab + R-CHOP (Arm 2C) in frontline RT (n=30) delivered an ORR of 77% (63% CR), with median OS 16.4 months and PFS 16.0 months.
Safety was consistent across arms: CRS occurred in up to 100% (mostly Grade 1/2) and resolved within days; treatment-related discontinuations and fatal events were infrequent.

Dec 8, 2025, 9:30 PM

Press Release

AbbVie outlines strategy and growth at Piper Sandler Healthcare Conference

ABBV

M&A

Guidance Update

Product Launch

AbbVie has executed roughly 30 transactions since early 2024, focusing on small bolt-on and platform deals (e.g., Nimble peptide platform, Capstan, 8Rx siRNA, Gubra obesity asset) while retaining capacity for larger M&A if compelling.
The company reaffirms high single-digit revenue growth from 2024–2029 with EPS expected to grow faster via operating margin expansion—driven by SG&A leverage—while maintaining R&D spend at ~15% of sales.
Skyrizi grew 46% YoY in Q3 2025 across IBD and psoriatic disease, benefiting from unique eight-week dosing and an on-body device; subcutaneous induction data in Crohn’s due H1 2026.
The Parkinson’s franchise led by Vyalev 24-hour infusion pump targets >$400 million in 2025 revenue, with full-year guidance >$1 billion and multi-billion peak potential alongside tavapadon.

Dec 3, 2025, 1:30 PM

Transcript

AbbVie outlines capital deployment and pipeline strategy at Piper Sandler Conference

ABBV

M&A

Guidance Update

AbbVie has completed ~30 smaller-scale BD transactions since early 2024, focusing on platform and single-asset deals across immunology, oncology, neuroscience, eye care and obesity, and remains open to larger near-term revenue deals if compelling.
The company maintains high single-digit revenue growth guidance for 2024–2029, with EPS expected to grow faster via operating margin expansion driven by SG&A leverage and continued R&D investment at ~15% of sales.
Skyrizi grew 46% YoY in Q3 with balanced IBD and psoriatic disease uptake; an on-body sub-Q induction device for Crohn’s is expected to initiate submission after H1 2026 data.
Pipeline highlights include phase II combination studies in IBD (TL1A, α4β7, IL-1), an obesity asset from the Gubra acquisition, and Rinvoq’s vitiligo label expansion targeting >$2 billion peak sales.
In neuroscience, Vyalev’s 24-hour sub-Q infusion is guiding >$400 million in 2025 sales with a >$1 billion peak outlook alongside filed tavapadon; brexalosin neuroplastogen shows a rapid 2-hour psychedelic effect in MDD with a favorable 5-HT2B antagonism safety profile.

Dec 3, 2025, 1:30 PM

Transcript

AbbVie outlines growth strategy and pipeline at Piper Sandler Healthcare Conference

ABBV

Guidance Update

New Projects/Investments

AbbVie is deploying capital through ~30 small platform and single-asset transactions since early 2024 to bolster its pipeline and sustain growth into the next decade.
The company reiterated high-single-digit revenue growth guidance for 2024–2029, with EPS expected to outpace sales via stable R&D spend (~15% of sales) and operating margin expansion through SG&A leverage.
Commercially, Skyrizi grew 46% YoY in Q3, the IL-23 category in ulcerative colitis rose from ~4% to ~40% in 18 months, and a sub-Q induction on-body device submission is planned for H1 2026.
Pipeline highlights include Rinvoq in vitiligo (>$2 billion peak sales), Vyalev Parkinson’s pump guiding >$400 million in 2025 and >$1 billion soon plus tavapadon filing, and Brotosilicin featuring a 2-hour neuroplastogen profile with 5-HT2B antagonism to reduce cardiac risk.

Dec 3, 2025, 1:30 PM

Transcript

AbbVie to feature new data at ASH 2025 Congress

ABBV

AbbVie will present new clinical data across multiple blood cancers—MM, FL, CLL, DLBCL, AML and AL—highlighting T-cell engagers, BCL-2 inhibitors and ADCs at the 2025 ASH Congress.
In the Phase 3 EPCORE FL-1 trial, epcoritamab + rituximab + lenalidomide reduced risk of progression/death by 79% (HR 0.21), with ORR 95.7% vs 81.0%, and CR 74.5% vs 43.3% for R2 alone.
The Phase 3 CLL17 trial met non-inferiority for fixed-duration venetoclax+obinutuzumab and venetoclax+ibrutinib versus continuous ibrutinib, with 3-year PFS ~81% (VO), 81.0% (I) and 79.4% (VI).
Early data show etentamig + pomalidomide/dexamethasone achieved ORR 81% and ≥VGPR 72% in R/R MM, and PVEK + venetoclax + azacitidine achieved CR 63.3% in newly diagnosed AML unfit for intensive chemotherapy.

Dec 2, 2025, 1:15 PM

Press Release

AbbVie receives positive reimbursement recommendation for SKYRIZI in ulcerative colitis

ABBV

Canada’s Drug Agency recommended SKYRIZI® (risankizumab) for reimbursement under public drug plans for adults with moderately to severely active ulcerative colitis who have failed prior therapies.
The recommendation is informed by evidence from pivotal phase 3 trials, including MOTIVATE, ADVANCE, FORTIFY (for Crohn’s disease) and INSPIRE, COMMAND (for ulcerative colitis).
AbbVie signed a Letter of Intent with the pan-Canadian Pharmaceutical Alliance to finalize reimbursement terms for SKYRIZI® in ulcerative colitis.

Nov 28, 2025, 12:01 PM

Press Release

AbbVie announces FDA approval of EPKINLY+R2 for relapsed/refractory follicular lymphoma

ABBV

Product Launch

The FDA approved EPKINLY® (epcoritamab-bysp) combined with rituximab and lenalidomide (R2) as the first bispecific antibody combination therapy for adult patients with relapsed/refractory follicular lymphoma after ≥1 prior systemic therapy.
In the Phase 3 EPCORE FL-1 trial, EPKINLY + R2 reduced the risk of disease progression or death by 79% (HR 0.21; 95% CI: 0.13–0.33; p<0.0001) and achieved an 89% overall response rate (vs 74% for R2 alone).
Among patients receiving EPKINLY + R2, 74% attained a complete response (vs 43% with R2), and median progression-free survival was not reached vs 11.2 months for R2.
This approval represents EPKINLY’s third indication and converts its accelerated approval granted in June 2024 into full approval; the safety profile was consistent with known regimen effects.

Nov 18, 2025, 5:47 PM

Press Release

Xilio Therapeutics presents Phase 2 vilastobart data in MSS mCRC

ABBV

Presented 40% objective response rate (ORR) in heavily pre-treated MSS mCRC patients without liver metastases and high plasma TMB, with statistically significant correlation (p = 0.05) between TMB status and response.
As of May 12, 2025, 44 patients were treated with vilastobart plus atezolizumab (100 mg Q6W and 1200 mg Q3W), including 27 without liver metastases and 24 evaluable for plasma TMB.
Approximately 55% of non-MSI-H CRC patients were plasma TMB-high (≥10 mutations/Mb), highlighting the potential of plasma-based TMB assays over traditional tissue-based tests.
Combination therapy was generally well-tolerated, with most treatment-related adverse events Grade 1–2, a 5% discontinuation rate and 7% incidence of colitis.

Nov 7, 2025, 2:05 PM

Press Release

Earnings Transcripts

Quarterly earnings call transcripts for AbbVie.

Q3 2025

Oct 31, 2025

→

Q2 2025

Jul 31, 2025

→

Q1 2025

Apr 25, 2025

→

View All Transcripts

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Robert A. Michael say about margins?What are AbbVie's strategic priorities?How is AbbVie positioned vs competitors?How did AbbVie do last quarter?

AbbVie (ABBV)

Analyst Earnings Quarterly Reports

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Executives

Robert A. Michael

Azita Saleki-Gerhardt

Jeffrey R. Stewart

Perry C. Siatis

Scott T. Reents

Board Members

Brett J. Hart

Edward J. Rapp

Frederick H. Waddell

Jennifer L. Davis

Melody B. Meyer

Rebecca B. Roberts

Robert J. Alpern

Roxanne S. Austin

Susan E. Quaggin

Thomas C. Freyman

Thomas J. Falk

William H.L. Burnside

Analyst Coverage

Christopher Schott

Mohit Bansal

Steve Scala

Terence Flynn

Vamil Divan

David Risinger

Asad Haider

Carter L. Gould

Courtney Breen

Geoffrey Meacham

Luisa Hector

Trung Huynh

Chris Shibutani

Geoff Meacham

James Shin

Matthew Phipps

Simon Baker

Timothy Anderson

Alexandria Hammond

Christopher Raymond

David Amsellem

David Aslam

Evan Seigerman

Gary Nachman

Jon Win

Tim Anderson

Latest news

Earnings Transcripts

Q3 2025

Q2 2025

Q1 2025

Ask Fintool AI Agent